Title :

Is nonanatomic rectal resection a valid therapeutic option for rectal gastrointestinal stromal tumors? A proposed decision algorithm

Author(s) :

Romain, Benoit [Auteur]
Delhorme, Jean‐baptiste [Auteur]
Manceau, Gilles [Auteur]
Sorbonne Université - Faculté de médecine [CHU Pitié Salpétrière]
CHU Pitié-Salpêtrière [AP-HP]
Lefevre, Jérémie [Auteur]
Sorbonne Université - Faculté de Médecine [SU FM]
CHU Saint-Antoine [AP-HP]
Tresallet, Christophe [Auteur]
Université Paris 13 [UP13]
Hôpital Avicenne [AP-HP]
Mariani, Pascale [Auteur]
Département de chirurgie
Iannelli, Antonio [Auteur]
Université Côte d'Azur [UniCA]
Hôpital Archet 2 [Nice] [CHU]
Centre Hospitalier Universitaire de Nice [CHU Nice]
Rouanet, Philippe [Auteur]
Institut régional de Cancérologie de Montpellier [ICM]
Piessen, Guillaume [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Brigand, Cécile [Auteur]
Interface de Recherche Fondamentale et Appliquée en Cancérologie [IRFAC - Inserm U1113]

Journal title :

JOURNAL OF SURGICAL ONCOLOGY

Pages :

1639-1646

Publisher :

Wiley-Blackwell

Publication date :

2020-09-16

ISSN :

0022-4790

HAL domain(s) :

Sciences du Vivant [q-bio]/Cancer

English abstract : [en]

Abstract Background and objectives The best surgical approach to rectal gastrointestinal stromal tumors (GISTs) is still debated, and both nonanatomic rectal resection (NARR) and anatomic rectal resection (ARR) are applied. ...
Show more >Abstract Background and objectives The best surgical approach to rectal gastrointestinal stromal tumors (GISTs) is still debated, and both nonanatomic rectal resection (NARR) and anatomic rectal resection (ARR) are applied. The aim of this study was to evaluate the feasibility and oncological outcomes of NARR and ARR for rectal GISTs (R‐GISTs). Methods Through a large French multicentre retrospective study, 35 patients were treated for R‐GIST between 2001 and 2013. Patients who underwent NARR and ARR were compared. Results There were 23 (65.7%) patients in group ARR and 12 (34.3%) in group NARR. Significantly more patients in the group with ARR had a neoadjuvant treatment (86%) with tyrosine kinase inhibitor (TKI) (imatinib) compared to those with NARR (25%) ( p < .01). The median preoperative tumor size was significantly different between the groups without and with neoadjuvant TKI: 30 ± 23 mm versus 64 ± 44.4 mm, respectively ( p < .001). Overall postoperative morbidity was 20% ( n = 7) (26% for ARR vs. 8% for NARR; p = .4). After a median follow‐up of 60.2 (3.2–164.3) months, the 5‐year disease‐free survival rates were 79.5% (confidence interval [CI] 95%: 54–100) for the NARR group and 68% (CI 95%: 46.4–89.7) for the ARR group ( p = .697), respectively. Conclusion The use of NARR for small R‐GIST's does not seem to impair the oncological prognosis.Show less >

Language :

Anglais

Peer reviewed article :

Oui

Audience :

Internationale

Popular science :

Non

Collections :

• Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) - UMR 9020 - UMR 1277

Source :

Harvested from HAL